Bicycle Therapeutics PLC (BCYC)
21.38
-0.80
(-3.63%)
USD |
NASDAQ |
May 17, 16:00
21.38
0.00 (0.00%)
After-Hours: 20:00
Bicycle Therapeutics Net Income (Quarterly): -26.56M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -26.56M |
| December 31, 2023 | -49.10M |
| September 30, 2023 | -49.90M |
| June 30, 2023 | -42.60M |
| March 31, 2023 | -39.06M |
| December 31, 2022 | -29.98M |
| September 30, 2022 | -28.35M |
| June 30, 2022 | -26.83M |
| March 31, 2022 | -27.56M |
| December 31, 2021 | -18.04M |
| September 30, 2021 | -14.68M |
| June 30, 2021 | -17.91M |
| March 31, 2021 | -16.19M |
| Date | Value |
|---|---|
| December 31, 2020 | -17.43M |
| September 30, 2020 | -10.14M |
| June 30, 2020 | -12.12M |
| March 31, 2020 | -11.32M |
| December 31, 2019 | -4.406M |
| September 30, 2019 | -9.482M |
| June 30, 2019 | -10.22M |
| March 31, 2019 | -6.503M |
| December 31, 2018 | -6.641M |
| September 30, 2018 | -7.692M |
| June 30, 2018 | -4.979M |
| March 31, 2018 | -2.534M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-49.90M
Minimum
Sep 2023
-4.406M
Maximum
Dec 2019
-23.09M
Average
-17.98M
Median
Net Income (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | -9.507M |
| TC BioPharm (Holdings) PLC | -- |
| Adaptimmune Therapeutics PLC | -48.50M |
| Verona Pharma PLC | -25.79M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 19.53M |
| Total Expenses (Quarterly) | 51.32M |
| EPS Diluted (Quarterly) | -0.62 |
| Enterprise Value | 387.05M |
| Profit Margin (Quarterly) | -136.0% |
| Earnings Yield | -20.83% |
| Normalized Earnings Yield | -20.85 |